Featuring online engagement, assessment and scheduling, as well as in-person clinical testing and logistics, TourHealth is a scalable COVID-19 testing solution that promises rapid results.
The TourHealth partnership has been awarded a contract by the State of Florida to provide two semi-permanent testing sites in city of Miami and Miami Beach.
At each site, TourHealth will be able to process up to 625 tests per day for a total of 1,250 tests daily.
In Utah, the TourHealth partnership was selected as one of two vendors approved for a multi-vendor contract vehicle to provide scheduling, call center and test collection relating to COVID-19 testing for state agencies, local governments and educational institutions.
Under the TourHealth partnership, NIC will provide its Gov2Go technology solution, a mobile platform and personal government assistant, for citizen engagement, assessment and scheduling purposes.
Impact Health will supply credentialled clinical professionals to staff the testing units and provide testing results quickly and securely to individuals and government, integrating results with government contact tracing programs. Next Marketing will be responsible for onsite logistics, including supplying mobile testing units, site design, signage and operational support, as applicable.
NIC (NASDAQ: EGOV) is a leading digital government solutions and payments company, serving more than 7,000 federal, state and local government agencies across the nation.
Impact Health is in providing field-based health and wellness services and has led efforts to combat the COVID-19 pandemic through temperature scanning and testing with various FDA/EUA approved kits.
Impact Health supports both private and public sector clients including Yale New Haven Health, Ashley Furniture, CBS Broadcasting and the State of Kansas.
Next Marketing is in developing, executing and managing mobile tour solutions for corporate and government clients including the US Air Force, Air National Guard, General Motors, and Continental Tire.
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
FDA approves WELIREG and LENVIMA combination for previously treated advanced renal cell carcinoma
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Clene Inc closes registered direct offering of common stock to existing shareholders